For healthcare professionals
Clinical documentation for independent review
Full formulation transparency. Published drug interaction documentation. Evidence-based ingredient rationale for every component.
What makes this formulation clinically distinct
MTHFR bypass
Active-form B-vitamins throughout
All seven B-vitamins in active coenzyme forms: benfotiamine (B1), R5P (B2), niacinamide (B3), P5P (B6), L-5-MTHF (B9), methylcobalamin (B12). Bypasses MTHFR impairment affecting up to 40% of patients. Bypasses hepatic and GI conversion limitations under treatment conditions.
Tocotrienols, not alpha-tocopherol
The deliberate vitamin E choice
Standard alpha-tocopherol carries concerns about interfering with chemotherapy's oxidative mechanism. Tocotrienols carry none of that concern and are 40–60× more effective as membrane antioxidants. NF-κB inhibition provides additional benefit.
Full gut architecture
Not a single-strain probiotic
10-strain probiotic blend (RCT mucositis evidence) + bovine colostrum (EGF, TGF-β, IgG/A/M) + 7 digestive enzymes + three prebiotic fibres. Full gut restoration system addressing dysbiosis, mucositis, and malabsorption simultaneously.
ECOG RCT evidence for CRF
Acetyl L-carnitine — phase III evidence
ALCAR crosses the blood-brain barrier, addressing CNS-mediated fatigue. Combined with niacinamide (NAD+ repletion — depleted by PARP activation from chemotherapy) and MCT (non-glucose energy substrate).
D3 CWS + K2 MK-7
Pan-treatment bone and immune support
D3 in cold-water-soluble micellar form — reliable absorption independent of fat digestion status. K2 as MK-7 with 72-hour plasma half-life. Primary across all treatment modalities, not only hormone therapy — 60–90% of patients are D-insufficient at diagnosis.
Chelated minerals throughout
Bisglycinate and AAC forms
All minerals in chelated forms with demonstrated superiority over inorganic salts in GI-compromised environments. Specifically relevant for magnesium in platinum-based regimens (renal wasting) and wherever gut integrity is compromised by treatment.
Patient selection — when to consider Nutrovene
Patient presentation
Nutrovene relevance
NRS-2002 ≥3 or PG-SGA B/C
Core indication.
Multi-layer formulation addresses the full nutritional picture — not only calorie deficit. Particularly relevant where gut absorption is compromised by treatment.
Weight loss >5% / cachexia risk
Anti-cachexia protein matrix + ALCAR + MCT.
Addresses both the protein building blocks and the metabolic environment driving catabolism.
Chemotherapy with gut side effects
L5 gut architecture.
Probiotics (mucositis RCT), colostrum EGF, enzymes, prebiotics. Xylitol for xerostomia. Half-serving titration guidance for GI adjustment.
Hormone therapy (AI or ADT)
D3 CWS + K2 MK-7 for CTIBL.
Substantially superior to D3 alone. K2 MK-7 pharmacokinetics maintain sustained bone protection from a single daily dose.
Cancer-related fatigue
ECOG phase III RCT acetyl L-carnitine + niacinamide (NAD+).
Addresses CRF at the mitochondrial level — not a stimulant. Relevant across all treatment modalities.
Post-surgical rehabilitation
Protein matrix + zinc + vitamin C + colostrum EGF.
D3 CWS for post-surgical fat malabsorption. ALCAR for post-operative fatigue distinct from anaemia.
Immunotherapy
Probiotic blend (microbiome diversity for response).
D3 CWS (immune regulation). Iodine reserve for thyroiditis risk. Individual assessment in active irAE.
Poor ONS tolerance or dysgeusia
Xylitol + MCT + dysgeusia-tolerant formulation.
Half-serving titration option. Designed for tolerability under treatment-induced palatability challenges.
Safety, precautions, and individual assessment
The complete Drug Interaction Guide is available from medical@nutrobio.com. The following covers the primary clinical considerations.
Guidance
Anticoagulants (warfarin)
Bromelain has additive anticoagulant effect — INR monitoring warranted. Acetyl L-carnitine may also potentiate. Flag to prescribing clinician.
Severe neutropaenia (ANC <0.5 × 10⁹/L)
Probiotic blend — individual risk-benefit assessment. Discuss with treating oncologist before recommending.
Post-allogeneic stem cell transplant
Beta-glucan activates innate immune cells — caution in GvHD setting. Haematologist review recommended.
Antifolate chemotherapy
L-5-MTHF theoretical pharmacological interaction with methotrexate and pemetrexed. Oncologist review before initiating.
Hypercalcaemia / granulomatous disease
Vitamin D3 contraindicated. Check serum calcium before initiating.
Cow's milk protein allergy
Contains whey and bovine colostrum — not suitable. Lactose intolerance is different and generally tolerated.
Antibiotics (any)
Separate from antibiotic doses by minimum 2 hours to preserve probiotic viability.
Quinolone or tetracycline antibiotics
Iron bisglycinate may reduce absorption — separate by 2 hours minimum.
Beta-alanine paraesthesia
Mild tingling sensation is harmless and transient — advise patients in advance to prevent alarm.
Monitoring protocol: Week 1–2: tolerability (gut adjustment, paraesthesia). Week 4: compliance and symptomatic check. Week 8: NRS-2002/PG-SGA, weight, patient-reported fatigue, quality of life (EORTC QLQ-C30 or FACT-G where available).
Clinical resources — available on request
Resource
Contents and availability
HCP Mechanisms of Action Brief
Full ingredient-level evidence documentation with references.
Every ingredient with its specific oncology rationale, evidence base, and pharmacological form justification. Available from medical@nutrobio.com.
Complete drug-nutrient interaction profile for all ingredients.
Formatted for clinical reference with monitoring recommendations. Available from medical@nutrobio.com.
Oncology Dietitian Guide
Clinical guidance for dietetic practice.
Patient selection, monitoring protocol, safety precautions, and the clinical conversation with patients and colleagues.
Treatment Integration Reference
Treatment-by-treatment clinical mapping.
Each major cancer therapy mapped to the biological disruptions it creates and the Nutrovene layers that address them.
Cancer as a Metabolic Disease — Scientific Brief
The metabolic science foundation.
Warburg effect, cachexia pathophysiology, mitochondrial dysfunction, and the nutritional oncology response. For oncologists and pharmacists.
Product samples
Available for patient trial before commitment.
Request via medical@nutrobio.com